Director/Senior Director, Business Development

Business Development Cambridge, MA


Description

Who are we?

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its commercialization, research, and development efforts in hematologic and pulmonary diseases. In hematology, REBLOZYL® (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the United States and are also developing luspatercept for the treatment of anemia in patient populations of MDS, beta-thalassemia, and myelofibrosis. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having recently presented positive topline results of the PULSAR Phase 2 trial. The Company is currently planning multiple Phase 3 trials with the potential to support its long-term vision of establishing sotatercept as a backbone therapy for patients with PAH at all stages of the disease.

 

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

 

What’s in it for you?

Acceleron is searching for a creative, resourceful, integrative individual with strong scientific and transaction experience for an important role to lead our various business development activities. This highly visible role will be responsible for identifying, evaluating and negotiating value-creating new business opportunities and strategic partnerships in support of Acceleron’s corporate strategy. This role will also require building strong relationships within the research and biotech community and develop recommendations to drive inorganic value for Acceleron.

 

What will you be doing?

  • Lead all aspects of certain business development activities (in and out-partnering), up until key stakeholder decision-making point
  • Work with Corporate Strategy team to identify areas of innovation and growth opportunities
  • For in-partnering, lead cross-functional team to screen and analyze potential collaboration opportunities from a scientific/medical, commercial, and strategic perspective, and manage detailed diligence on selected high-priority deals as part of diligence teams
  • For out-partnering, lead cross-functional team to develop internal program presentation material, accurate and with a strategic focus to maximize the value of the project, and manage information disclosures toward potential partners
  • Build business cases, including appropriate transaction financial structure for prospective partnering opportunities
  • Lead structuring, negotiation and execution of deals and transactions
  • Lead or contribute to new strategic partnering initiatives not necessarily defined as in- or out-partnering
  • Establish and cultivate relationships with external partners and experts to bring forward innovative ideas
  • Stay closely abreast of research developments in the specialty pulmonary, hematology, cardiovascular, renal and hepatology fields via published literature, trade press, conferences, patent filings, and relationships across academia and industry
  • Collaborate closely with other BD team members to achieve the team’s objectives
  • Serve as an ambassador of Acceleron’s BD function and promote Acceleron as the partner of choice at business partnering meetings and scientific conferences

What are we looking for?

  • 10+ years business development experience with at least 5+ years of assuming lead role in deal execution
  • Understanding of complex deal structures requiring coordination with finance, legal, tax, R&D and commercial stakeholders
  • Proven track record at sourcing, structuring, negotiating and closing different types of partnerships from discovery stage assets through commercialization stage
  • Knowledge of the drug development and commercialization process
  • Financial modelling and commercial forecast experience
  • Established network of contacts in key academic institutions, biotechnology and pharmaceutical companies, VC community
  • Process-minded with the ability to be flexible and nimble when appropriate
  • An energetic, problem solver who is effective at detecting and managing risk, while providing quick responses to emerging problems
  • Experience working with all levels of management and consulting with key business stakeholders with ability to influence for greater outcomes
  • Strong team player that has a customer-centric approach and is solution oriented
  • Attention to detail and the ability to work individually, within a multi-disciplinary team, as well as with external partners and vendors
  • Ability to synthesize and present to senior executives, including Board, a complex set of facts (i.e. scientific, clinical, financial, and market information) to facilitate the decision-making process
  • Possesses strong written and verbal communication skills
  • Excitement about the vision and mission at Acceleron
  • Ability to travel internationally and domestically on a regular basis
  • Flexibility to accommodate teleconferences outside of regular working hours
  • Must thrive working in a fast-paced, innovative environment while remaining flexible, proactive, resourceful and efficient
  • Excellent interpersonal skills, ability to develop important, cross-functional and cross-cultural relationships with key stakeholders, ability to identify and raise issues to key stakeholders in order to develop relevant and realistic plans, programs and recommendations
  • Bachelor's Degree is required, while an advanced degree (MBA, MD and/or PhD) is strongly preferred

How will you grow with us?

This role provides an exciting opportunity to be a key player in furthering the company’s goal of becoming a leader in the specialty pulmonary and hematology space as well as expanding into adjacent therapeutic areas. As part of a dynamic team, you will have the opportunity to engage and lead workstreams that impact all areas of the organization. Workstreams are typically composed of multiple stakeholders within R&D, Commercial or Enabling Functions, including cross functional working teams, executive level leadership and decision committees. With one approved product, and an exciting pipeline, Acceleron is in a phase of dynamic growth with opportunities to make a positive impact on patients’ lives. If you are looking to be a part of an innovative and fast-paced environment, join our team!

*In compliance with federal law, all persons hired will be required to verify identity and eligibility to work in the United States and complete the required employment eligibility verification document form upon hire.

*Recruiters - please do not send unsolicited resumes to this posting.

FOR IMMEDIATE CONSIDERATION PLEASE SUBMIT YOUR RESUME TO:

www.acceleronpharma.com

 

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair. Acceleron focuses its research, development, and commercialization efforts in pulmonary and hematologic diseases. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial. The Company is currently planning multiple Phase 3 trials with the potential to support its long-term vision of establishing sotatercept as a backbone therapy for patients with PAH at all stages of the disease. Acceleron is also investigating the potential of its early-stage pulmonary candidate, ACE-1334, which it plans to advance into a Phase 1b/2 trial in systemic sclerosis-associated interstitial lung disease (SSc-ILD) next year. In hematology, REBLOZYL® (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the United States and are also developing luspatercept for the treatment of anemia in patient populations of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.